XML 38 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
May 31, 2021
Dec. 31, 2020
Disaggregation of Revenue [Line Items]            
Revenue $ 142,000 $ 15,699,000        
Upfront cash payment received 53,683,000   $ 52,096,000 $ 81,572,000    
Collaboration Agreement with AstraZeneca            
Disaggregation of Revenue [Line Items]            
Revenue 100,000 14,700,000        
Upfront cash payment received         $ 40,000,000 $ 20,000,000
Milestone payments received 0 10,000,000 $ 10,000,000      
Research Collaboration Income            
Disaggregation of Revenue [Line Items]            
Revenue $ 142,000 $ 15,556,000